PD-L1 Antibodies with Engineered Variable Domains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments targeting PD-L1 protein are limited in their ability to specifically bind and effectively inhibit PD-L1, leading to suboptimal immune activation against tumors.
Innovation Solution
Development of isolated antibodies or antigen-binding fragments with specific amino acid sequences in their heavy and light chain variable domains, capable of binding to PD-L1 with high affinity, allowing for targeted therapy and potential combination with other immune checkpoint inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments targeting PD-L1 protein are used, then treatment can be administered, but binding affinity and immune activation are insufficient
Solution Approach 1:
The patent modifies the amino acid sequences in the variable domains of the antibody heavy and light chains to optimize binding parameters. Specifically, the CDR regions are engineered to achieve higher affinity for PD-L1, transforming the physical-chemical parameters of the antibody-PD-L1 interaction to overcome insufficient binding and enhance immune activation effectiveness
Solution Approach 2:
The patent focuses optimization on specific local regions of the antibody molecule, particularly the complementary determining regions (CDRs) in the variable domains. By enhancing the binding quality at these critical interface regions through targeted amino acid substitutions, the overall affinity and effectiveness are improved without requiring complete redesign of the entire antibody structure
2Reliability
If antibodies with high binding affinity to PD-L1 are developed, then therapeutic effectiveness is improved, but development complexity increases
Solution Approach 1:
The patent divides the antibody molecule into functional segments, focusing modifications on the variable domains and particularly the CDR regions while maintaining the standard constant domains. This segmentation allows targeted optimization of binding affinity through localized sequence changes without complicating the overall antibody architecture, thereby improving therapeutic effectiveness while controlling development complexity
Solution Approach 2:
The patent designs antibodies that maintain universal structural features of IgG molecules, allowing them to perform multiple functions including high-affinity PD-L1 binding, Fc-mediated effector functions, and compatibility with standard antibody production and delivery platforms. This multi-functionality approach achieves enhanced therapy without proportionally increasing overall system complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies demonstrate strong binding affinity to PD-L1, enhancing T-cell activity and providing a therapeutic strategy for various cancers by restoring immune surveillance against tumor cells.
Implementation Method 1
isolated antibodies or antigen-binding fragments with specific amino acid sequences in their heavy and light chain variable domains, capable of binding to PD-L1 with high affinity
Data Source
AI summary
The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes PD-L1. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen binding fragment thereof.